Algos Therapeutics Inc.
This article was originally published in Start Up
Executive SummaryThe founders of Algos Therapeutics decided to base their pain drug company in part on revenues it could generate by providing pharmaceutical clients with preclinical pain drug testing services. The company has built a growing stream of fee-for-service clients, which makes it self sustaining, the company says.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.